CDC Delays Infant Hepatitis B Vaccine Schedule, Studies Warn of Higher Infection Risk

On December 5, 2025, the CDC's Advisory Committee on Immunization Practices voted 8-3 to end the universal recommendation that all newborns receive a hepatitis B vaccine within 24 hours of birth — a policy that had been in place since 1991 [1]. The CDC formally adopted the recommendation on December 16, shifting the hepatitis B birth dose from a universal standard to "shared clinical decision-making" for infants born to mothers who test negative for the virus [2]. Within weeks, multiple peer-reviewed and preprint modeling studies warned the change would lead to thousands of preventable chronic infections, hundreds of liver cancer cases, and billions of dollars in excess healthcare costs over the coming decades [3][4].

The policy reversal has split the medical establishment. The American Academy of Pediatrics called it a decision with "heartbreaking" consequences and announced it would continue recommending the birth dose [5]. Sen. Bill Cassidy (R-La.), a physician, called it "a mistake" that "makes America sicker" [1]. Meanwhile, several members of the reconstituted ACIP defended the vote as restoring parental choice and aligning U.S. practice more closely with some European schedules [6].

What Changed — and Why

Under the previous policy, all infants in the United States were recommended to receive the first dose of hepatitis B vaccine within 24 hours of birth, regardless of their mother's hepatitis B status. The new recommendation preserves the birth dose only for infants born to mothers who are hepatitis B surface antigen (HBsAg)-positive or whose status is unknown. For all other newborns — the vast majority — parents and clinicians now decide together whether and when to begin the series, with ACIP suggesting a start no earlier than two months of age [2].

The stated rationale from ACIP members who voted in favor cited three factors: parental concerns about administering vaccines to newborns, the practice in several European countries of beginning the series later in infancy, and the extended period since the last formal policy review [1]. No new safety concerns or effectiveness data prompted the reconsideration [1].

The vote took place after the Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., reconstituted ACIP in mid-2025, removing 17 sitting members and appointing new ones [7]. Among the new appointees who voted to end the universal birth dose were Robert Malone, an mRNA technology researcher who has been a prominent COVID-19 vaccine skeptic; Retsef Levi, an MIT operations management professor with no medical training who characterized the vote as "a fundamental change in the approach"; and Evelyn Griffin, an OB-GYN who questioned whether the policy was "asking our babies to solve an adult problem" [6][8].

Three members voted against. Their identities have been reported but the specific reasoning each offered during the closed deliberations has not been fully published [1].

The Epidemiological Stakes

Births to HBsAg-Positive Mothers

An estimated 17,827 infants were born to HBsAg-positive women in the United States in 2021, representing roughly 0.5% of all births [9]. Non-U.S.-born women accounted for 57.9% of these births despite comprising only 21.5% of total births, reflecting higher hepatitis B prevalence in many countries of origin [9]. Infants born to mothers positive for both HBsAg and hepatitis B "e" antigen (HBeAg) face a 70–90% chance of acquiring perinatal infection, and 85–90% of those infected will develop chronic hepatitis B [10].

The birth dose was designed to catch infants whose mothers were not screened, were screened inaccurately, or whose status changed during pregnancy. Before universal birth-dose vaccination began in 1991, the CDC estimated 16,000–18,000 perinatal hepatitis B infections occurred annually in the United States [2].

Modeling the Impact of Delay

Two major modeling efforts have projected the consequences of the policy change.

The University of Minnesota's Vaccine Integrity Project reviewed approximately 400 studies spanning 40 years and concluded there was "no evidence that delaying the universal hepatitis B vaccine birth dose improves safety or effectiveness" — only risks [11]. Their modeling found that if vaccination were delayed to 12 years of age, more than 2,700 preventable hepatitis B infections would occur in the first year, leading to 503 cases of liver cancer and 788 hepatitis B-related deaths over those children's lifetimes, with excess medical costs exceeding $300 million [3].

A separate analysis from Emory University researchers, published through HepVu, modeled multiple delay scenarios specifically. For the two-month delay that most closely matches the new ACIP recommendation — including infants of mothers with unknown hepatitis B status — the model projected at least 1,437 additional infections among children per year, along with 304 cases of liver cancer and 482 hepatitis B-related deaths over those cohorts' lifetimes [4].

Source: HepVu / Emory University Analysis

Data as of Dec 1, 2025CSV

The Emory analysis noted these figures are likely underestimates because they assume maternal screening is universal and perfectly accurate — conditions that do not hold in practice [4]. A Cornell study published in JAMA Pediatrics in April 2026 reinforced these findings, estimating costs ranging from $16 million to $370 million depending on the length and scope of the delay [12]. Lead researcher Dr. Noele Nelson stated: "Our study underestimates the costs and health outcomes associated with delays" due to conservative modeling assumptions [12].

Source: HepVu / Emory University Analysis

Data as of Dec 1, 2025CSV

Vaccination Rates Were Already Falling

The policy change arrived amid an existing decline in hepatitis B birth-dose coverage. A study of more than 12.4 million U.S. newborns, using electronic health records from over 1,800 hospitals, found that the birth-dose vaccination rate peaked at 83.5% in February 2023, then fell more than 10 percentage points to 73.2% by August 2025 [13].

Source: JAMA / Epic Cosmos EHR Data

Data as of Aug 1, 2025CSV

The decline coincided with heightened public skepticism about childhood vaccination following the COVID-19 pandemic, including media coverage and political discourse that influenced perceptions of vaccine safety [13]. The study, published in JAMA in February 2026, could not break out state-level or demographic data due to the use of deidentified, aggregated records [13]. However, earlier CDC data showed significant variation: New York City's birth-dose coverage was 74.4% in 2023, down from 77% in 2019 [14].

Public health researchers have warned that the new ACIP recommendation could accelerate this trend, particularly among populations already less likely to receive the birth dose.

The Cost Equation

Chronic hepatitis B is an expensive disease to manage over a lifetime. Systematic reviews estimate mean direct medical costs of $2,748 per year for chronic hepatitis B management, rising to $18,903 for compensated cirrhosis (scarring of the liver that has not yet caused liver failure), $35,668 for decompensated cirrhosis, and $93,228 for liver cancer [15]. Liver transplantation costs average $355,000 [15].

Without treatment, 31% of patients with active chronic hepatitis B will die of liver-related complications within 20 years, with 12% developing liver cancer [15].

The hepatitis B vaccine itself costs roughly $25–$50 per dose in the U.S. pediatric market [2]. The Emory/HepVu analysis estimated that even the most modest delay scenario — two months — would generate at least $222 million per year in excess healthcare costs. Over a decade, the cumulative excess ranges from $2.22 billion to $3.13 billion [4]. If additional screening infrastructure is required to identify at-risk infants who previously would have been covered by universal vaccination, the 10-year cost rises to $3.24–$4.09 billion [4].

How the U.S. Compares Internationally

Proponents of the delay have pointed to European countries that do not administer hepatitis B vaccine at birth. This comparison requires context.

The United Kingdom begins hepatitis B vaccination at 8 weeks as part of a hexavalent combination vaccine, with a targeted birth dose only for infants of HBsAg-positive mothers [16]. However, the UK has far lower hepatitis B prevalence than the U.S. — roughly 0.1–0.5% of the population, compared to an estimated 0.9–1.9 million chronic infections in the United States — and universal prenatal screening with high compliance rates [16][2].

Germany similarly begins at 2 months with a hexavalent vaccine, relying on comprehensive prenatal screening [17]. Australia and Canada both include birth-dose vaccination in their recommended schedules, particularly for at-risk infants [17].

The comparison is complicated by structural differences. European countries with delayed schedules tend to have universal healthcare systems with integrated prenatal screening, high rates of antenatal care attendance, and lower population-level hepatitis B prevalence. The U.S. has a more fragmented healthcare system, higher uninsured rates, and significant immigrant populations from high-prevalence countries — all factors that made universal birth-dose vaccination the preferred safety-net approach in 1991 [2][9].

The Case for Delay: Examined

The strongest argument for the policy change rests on parental autonomy and the principle that medical interventions should be proportionate to individual risk. For an infant born to a mother confirmed negative for hepatitis B, the immediate risk of perinatal transmission is essentially zero. ACIP member Evelyn Griffin framed this as a question of whether "we are asking our babies to solve an adult problem" [8].

Some ACIP members also cited the practice in European countries as evidence that delayed schedules can work safely when paired with robust screening [1].

On safety, the CDC's own review presented to ACIP in September 2025 found the hepatitis B birth dose has an established safety profile: injection-site pain in fewer than 10% of newborns, fever in 0–5.9%, and irritability in 1.5–22.1% [18]. No serious adverse events or deaths have been causally linked to the birth dose across more than 12 million administered doses [18]. A systematic review of preterm infants found minimal published data on prematurity-specific outcomes but no signal of increased risk [19].

The Vaccine Integrity Project's review of approximately 400 studies spanning four decades found no evidence supporting the claim that delaying the birth dose improves safety or effectiveness [11]. The presentations to ACIP by Cynthia Nevison, a climate researcher with ties to anti-vaccine organizations, and Aaron Siri, a lawyer who has sued vaccine manufacturers, were criticized by outside scientists for methodological shortcomings [7][8].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Academic publishing data reflects the intensity of scientific engagement on this topic: research publications on hepatitis B birth-dose vaccination peaked at 2,124 papers in 2023 and remained elevated through 2025, driven in part by the policy debate [20].

Insurance, Access, and Equity

The Georgetown University Center for Children and Families warned that the ACIP recommendation could cascade through insurance and public health systems [21]. ACIP recommendations directly determine which vaccines private insurers must cover without cost-sharing under the Affordable Care Act, and which vaccines qualify for the Vaccines for Children (VFC) program — a federal program providing free vaccines to uninsured and underinsured children [21].

If the hepatitis B birth dose is no longer universally recommended, insurers may adjust coverage, and VFC eligibility could narrow. Children from lower-income families and those without robust insurance would face the greatest barriers to access [21].

The National Medical Association, which represents Black physicians, noted that hepatitis B disproportionately affects Black and Asian American communities and called the vote "a threat to the health of the most vulnerable populations" [23].

Legal Precedent and Liability

Health Secretary Kennedy warned that vaccine recommendations diverging from the CDC's official schedule are not shielded from liability under the 1986 National Childhood Vaccine Injury Act [22]. However, legal scholars note that the AAP's continued recommendation of the birth dose creates a viable alternative standard of care. Hospitals and pediatricians following AAP guidance rather than the new CDC recommendation would likely retain legal protection under existing case law [22].

The liability question cuts both ways. Hospitals that follow the new CDC guidance and stop offering the birth dose routinely could face malpractice claims if an infant subsequently develops chronic hepatitis B — particularly if the mother's negative screening result was inaccurate. The shift to "shared decision-making" also places documentation burdens on providers who must now record informed consent discussions [22].

Historical precedent offers a cautionary parallel. When the UK temporarily suspended its whole-cell pertussis (whooping cough) vaccine in the 1970s due to safety concerns, vaccination rates dropped from over 80% to 31%, and a pertussis epidemic followed with over 100,000 cases and 36 deaths [2]. The episode is widely cited in public health literature as an example of how even temporary policy changes can cause lasting harm to vaccination coverage.

Under the National Childhood Vaccine Injury Act, vaccines on the recommended childhood schedule are covered by the Vaccine Injury Compensation Program (VICP), which provides a no-fault system for compensating vaccine injuries while shielding manufacturers and administrators from tort liability. Removing the hepatitis B vaccine from the universal schedule does not automatically remove it from the VICP, but it creates regulatory ambiguity that Kennedy's HHS has not clarified [22].

What Happens Next

The medical establishment is not unified in following the new guidance. The American Academy of Pediatrics announced it would continue recommending universal birth-dose vaccination [5]. Several state health departments, including New York, have issued advisories encouraging hospitals to maintain the birth dose [14]. Some neonatologists have stated publicly that they will not change their practice [22].

The real test will be whether vaccination rates — already declining — fall further. The JAMA study showing a 10-point drop before the policy change suggests the trajectory was concerning even before ACIP acted [13]. If rates continue to decline, the modeling studies project a steady accumulation of preventable chronic infections, each carrying a lifetime of medical costs and a 25% risk of premature death from liver disease [4][10].

The hepatitis B birth dose was introduced in 1991 as a safety net — an acknowledgment that screening programs, while important, would never catch every case. Thirty-four years later, the question is whether the United States has built a healthcare infrastructure reliable enough to make that safety net unnecessary, or whether removing it will expose the gaps that universal vaccination was designed to cover.